Targeted conditioning with iodine (131I) apamistamab enabled older patients with relapsed or refractory acute myeloid leukemia to undergo allogeneic hematopoietic stem cell transplantation, according to results of the phase 3 SIERRA trial.The findings, presented at 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, showed iodine (131I) apamistamab, known
CAR T-Cell Therapy Targeting GPRC5D Antigen Proves Effective in First Trial miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.